AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting May 13, 2025
AAVantgarde announces 2 presentations at ARVO 2025 annual meeting: LUCE-1 clinical trial data from Usher 1B program & NHP GLP data from Stargardt disease program March 10, 2025
AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B December 9, 2024
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa December 2, 2024
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy October 29, 2024
AAVantgarde Announces First Patient Dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 Study for Retinitis Pigmentosa Related to USH1B September 16, 2024
